Vishay Precision Group
This is the archived full research. Read the story
A maker of ultra-stable electronic parts and force sensors, riding record orders from chip-equipment makers and a first humanoid-robot customer.
The scores
Growth3/4 ↑
Revenue up 14.6% in the first half on real orders, but it tracks the chip-equipment cycle and follows a 13.7% fall in 2024.
Business quality2/4 →
Foil at the top of the specification is protected, but it is one slice of revenue; load cells compete on price and returns stay low.
Financial position4/4 →
About $65M of net cash and a revolver to 2029; Q3 adjusted free cash flow was positive at $5.5M after a negative first half.
Execution record2/4 ↓
Q3 landed inside the guide, but profit fell on Sensors' 21% growth, humanoid revenue is undisclosed, and operating margin fell from 11.8% to 2.7%.
Per share capture3/4 →
Share count down 2.5% since 2023 with no convertible, but no buyback now and share pay up 47.1% while excluded from adjusted profit.
Potential2/4 →
The upside is expected, not committed: a cancellable backlog, a humanoid nomination letter with no volume, and a margin plan above anything earned.
Risk profile3/4 →
One serious dependency, disclosed and survivable - its main factories are in Israel - plus an open export-control self-disclosure; no customer above 10%.
Valuation3/4 ↑
About 126.1 times operating profit, 87% of a three-stage value near $50.97 at an 8% return: fair, inside the 20% margin.
Evidence quality3/4 →
The profit gap is filed and current, but the humanoid half rests on management claims, one outside count and an unsigned letter.
If it works 0.8× · if it fails you keep about 76%.
The Verdict
We rate Vishay Precision Neutral. It makes ultra-stable electronic parts and force sensors, but orders have not reached profit, because head-office and new costs took nearly everything its businesses earned, so the business is mixed. On the analysts' path the price is a little under our value, but that path needs a margin above anything it has earned since listing in 2010, and our gloomy case sits close. As a bet on humanoid-robot sensors it is fragile: the customer has pushed its schedule back, and failure leaves a little over half.
The long caseIf humanoid robots leave the lab for factory floors in large numbers, each needs precise force sensing, and a supplier already nominated by one robot maker could ride that growth.
How we weighed it
The price against our value
Cuts both ways
Price at 87% of our value
The price is a little under our value, close to the bear case.
The business
Against it
Mixed
Ultra-stable parts and force sensors, but head-office and new costs take nearly everything the businesses earn.
Growth against what the price assumes
Cuts both ways
The value needs a margin above anything it has earned since listing.
What could go wrong
Against it
The chip cycle can turn, the main plants sit in Israel and the robot ramp may slip again.
Against competitors
Cuts both ways
There is no listed rival to compare directly.
How its group is behaving
Cuts both ways
It sits in none of our ranked groups; robot and chip-test demand move it.
The latest news and report
Against it
The last report repeated the pattern: orders grew but profit did not, and the robot ramp was pushed back.
The evidence under this - 7 claims
- 2026-11-04editedQ3 2026 orders added
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
- If Q2 2026's $3.3M currency hit reverses and the cost programme delivers its $20M, the target is closer than the 2.7% margin of 2025 suggests; management's own bridge put Q2 cash profit near $9M rather than $5.5M (C37).
- The humanoid option is sized in the target only at 50% a year; a real volume ramp at $150 to $250 a robot is not in the $60M.
- 2026-11-04editedre-struck at the 3 November close and the 3 October balance sheet
- 2026-11-06editedre-struck at the 2026-11-05 close of $41.22 after the shares fell 24% from the 2026-11-03 close
The company
VPG takes a metal foil a few thousandths of a millimetre thick and etches it into two kinds of part. One is a resistor that sets an exact voltage in a measuring circuit and barely drifts as it warms. The other is a strain gauge: glued to metal, it measures how hard the metal is being pushed.
Chip-test equipment, aircraft and satellites use the resistors; robot joints, scales and truck-weighing systems use the gauges. VPG also builds finished load cells, steel-mill gauges and crash-test recorders.
The evidence under this - 5 claims
- VPG's own risk factors say foil resistors and foil strain gages are also produced by competitors principally located in China, so the technology is not unique to VPG.
- Sensors gross margin was 31.5% in Q2 2026 and 28.5% in Q4 2025 - not what a part with no substitute usually earns, which says either the foil niche is a small part of the segment or its price is not set by scarcity.
- Thin film keeps closing the gap: a 5 ppm, 0.01% chip is already qualified for space by ESCC.
How it makes money
It sells parts and systems, one order at a time, through three businesses of similar size: Sensors ($115.6M of 2025 revenue), Weighing Solutions ($111.1M) and Measurement Systems ($80.4M).
Each business earns a profit, but a large head office sits on top. In 2025 the businesses earned $45.2M and head-office costs took $35.4M, leaving $8.3M of operating profit once a one-off gain from selling a factory is removed.
The evidence under this - 4 claims
Where the money comes from, stream by stream
| Stream | Share of sales (FY2025) | How it earns it |
|---|---|---|
| Sensors | 37.6% | Bulk Metal foil precision resistors and foil strain gages, designed into chip-test, avionics, medical and robot equipment under customer part numbers. |
| Weighing Solutions | 36.2% | Load cells and onboard truck weighing systems sold to scale, machinery and vehicle makers, where price is an important factor. |
| Measurement Systems | 26.2% | Steel-mill roll-force and strip gauges, Gleeble metallurgy simulators and DTS crash-test data loggers, sold as projects and systems. |
Who runs it
Ziv Shoshani has run VPG since it split from Vishay in 2010, and the same finance chief has been beside him since then. Profit margins peaked in 2022 and have since shrunk. Insiders own about 7% of the shares but, through a family trust's super-voting stock, about 29% of the vote. Bonuses ride on adjusted profit and margin, the long-term shares on earnings and cash, and neither the bonus nor those shares have paid out lately.
The evidence under this - 4 claims
The proxy prints the group's common stake as 1.7% of the class, while 374,104 of 12,274,522 shares is 3.0%; the share counts are used here, not the printed percentage.
Why it wins, and who could beat it
Why customers come back
A designer who needs a circuit to stay accurate as temperatures swing writes that exact foil part into the design. Changing it later means proving the circuit again, and for military and space parts, requalifying it.
The edge is real at the top: VPG's qualified military resistor drifts at most 2 parts per million per degree, while the best space-approved rival part is rated at 5. Below that, cheaper parts will do: Sensors kept about 31 cents of each sales dollar as gross profit in Q2 2026.
The evidence under this - 4 claims
- VPG's own risk factors say foil resistors and foil strain gages are also produced by competitors principally located in China, so the technology is not unique to VPG.
- Sensors gross margin was 31.5% in Q2 2026 and 28.5% in Q4 2025 - not what a part with no substitute usually earns, which says either the foil niche is a small part of the segment or its price is not set by scarcity.
- Thin film keeps closing the gap: a 5 ppm, 0.01% chip is already qualified for space by ESCC.
- The same 10-K says customers may cancel or reschedule backlog shipments, in many instances without penalty - a designed-in part still depends on the customer's own volumes.
- The second humanoid customer re-evaluated its design after two years of prototypes (C21): a design-in is not a lock until the programme freezes.
The threat
In robots, the attacker is the finished sensor. Novanta sells ready-made force sensors and names humanoids as a market, so a robot maker can buy the whole unit and never order VPG's gauges.
In resistors, Vishay Intertechnology's thin-film parts keep getting more precise, and in load cells and steel-mill gauges VPG competes with HBK, Zemic, ABB and others, where price decides.
The evidence under this - 4 claims
- VPG says it spent more than two years in engineering collaboration with its first humanoid customer and received a vendor nomination letter, so at least one maker chose VPG's parts after comparing them.
- A finished six-axis sensor is heavier and dearer than gages bonded into a joint, and a maker building at volume has a cost reason to integrate rather than buy the finished unit.
The rivals: NOVT, VSH, and 2 more that are private, in-house or listed abroad.
Who else does this, rival by rival
| Ticker | Rival | Where it competes | How far along | Priced against it |
|---|---|---|---|---|
| NOVT | Novanta's ATI Industrial Automation six-axis force torque sensorsPriced against it: Different product | Humanoid robot force sensing | On sale | Different product |
| VSH | Vishay Intertechnology's thin film precision chip resistors (the PHR and PFRR lines)Priced against it: One segment only | Sensors | On sale | One segment only |
| Not listed | HBK (Spectris) and Zemic load cellsPriced against it: Not listed | Weighing Solutions | On sale | Not listed |
| ABB and IMS rolling-mill measurement, and Kistler data acquisitionPriced against it: Listed abroad | Measurement Systems | On sale | Listed abroad |
How big it could get
How big this could get
The humanoid market is still tiny. An industry body counts about 7,000 humanoid robots sold worldwide in 2025, many bought for research. At the $400 to $500 of sensing parts management says each robot carries, that is about $3M, less than the roughly $4M VPG says it sold to robot makers that year.
So today's humanoid sales are prototypes. At volume, management expects $150 to $250 a robot, so thousands a week are needed to matter to a $330M company.
The evidence under this - 4 claims
- The CEO said on the same call that the market is very competitive and that vendors face pricing pressure; the volume price is an expectation, not a contract.
- Content per robot halves as volume rises, so unit growth overstates revenue growth by about 2 to 3 times.
- IFR's count excludes household and military humanoids and may undercount Chinese makers, so the true 2025 unit base could be larger.
- Prototype robots carry more sensing content per unit than production ones, so the $400 to $500 figure may understate 2025 content.
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
Who has signed
The first humanoid customer sent a formal supplier nomination, which names VPG but commits to no volume or price. Across the company, $135.8M of orders were waiting to ship in July 2026, $78.3M of them in Sensors, though customers can often cancel without penalty.
The evidence under this - 3 claims
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
- 2026-11-04editedeighth quarter at or above 1.0
- 2026-11-04editedQ3 2026 orders added
The results
The numbers
Sales grew 12% over the twelve months to Oct 2026, faster than the 0.2% in the year to Dec 2025.
Operating margin is 1.1%, down from 12% in the year to Dec 2023.
Running costs take 38¢ of each sales dollar, up from 31¢ in the year to Dec 2021.
Shareholders' money lost 1.0% a year, down from 7.6% in the year to Dec 2021.
It turned 0.4% of sales into free cash, $1.47M over the last twelve months.
It holds $80.9M of cash against $15.7M of debt, $65.2M more cash than it owes.
Yearly sales growth has ranged from −14% to +18% over the last 5 years, with sales falling in 2 of them.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-11-10. Fiscal years end in December.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | 12 mo to Oct 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $318M | $363M | $355M | $307M | $307M | $334M |
| Sales growth | +18% | +14% | −2.1% | −14% | +0.2% | +12% |
| Profit | ||||||
| Gross margin | 39% | 41% | 42% | 41% | 39% | 39% |
| Operating margin | 8.6% | 12% | 12% | 5.5% | 4.5% | 1.1% |
| Net margin | 6.4% | 9.9% | 7.2% | 3.2% | 1.7% | −1.0% |
| What growth costs, per sales dollar | ||||||
| Research and development | 5.4% | 5.5% | 5.7% | 6.5% | 6.8% | 6.7% |
| General and admin | - | - | 9.4% | 11% | 12% | 12% |
| Pay in shares | 0.7% | 0.7% | 0.6% | 0.3% | 0.6% | 0.8% |
| Capital spending | 5.4% | 5.9% | 4.3% | 3.0% | 2.6% | 4.1% |
| Cash | ||||||
| Cash from operations | $33.5M | $33.0M | $45.9M | $19.8M | $14.4M | $15.2M |
| Free cash flow | $16.5M | $11.7M | $30.7M | $10.7M | $6.35M | $1.47M |
| Balance sheet | ||||||
| Cash and short-term investments | $84.3M | $88.6M | $84.0M | $79.3M | $87.4M | $80.9M |
| Debt | $60.7M | $60.8M | $31.9M | $31.4M | $20.6M | $15.7M |
| Net cash | $23.6M | $27.8M | $52.1M | $47.8M | $66.8M | $65.2M |
| Returns and shares | ||||||
| Return on capital | 6.8% | 10% | 7.8% | 2.6% | 2.4% | - |
| Shares (diluted) | - | - | - | - | - | 13.4K |
What growth costs
Growth has been getting more expensive, not less. Overhead and research costs kept rising when sales fell and have grown faster than sales on the way back up, so each new dollar of sales has added little profit. Spending on factories has been cut.
The evidence under this - 2 claims
- On the last upswing the cost did lever: in 2022, with revenue up 14%, the line fell from 30.0 to 28.8 cents and operating margin rose to 12.1% (C24).
- The R&D figure is the segment note's disclosure (tagged ResearchAndDevelopmentExpense), not a separate income statement line, so the two definitions overlap rather than add.
- Management argues the spending is the price of capacity already ordered by customers and that profit follows once the new staff are productive; the Q1 2026 Sensors segment margin was 14.6%.
- Part of the unallocated rise is the 2026 move of share-based pay out of segment figures, which is presentation rather than new cost.
- 2026-11-04editedQ3 repeated the pattern for a second quarter
The last report (4 Nov)
Quarter ended October 2026, filed figures.
Q3 2026 adjusted sales rose 9.6% to $87.4M, inside the range the company promised, and orders topped $100M with sensors orders at a record. But adjusted operating margin was 4.9%, below our 5% line, and operating income fell to $2.7M.
Sensors revenue rose 21.3% while that business's profit fell 6.1%, because costs rose and currency cost $3.4M. The release gave no humanoid sales figure, saying only that the ramp follows the customer's updated schedule.
What it did to the thesisIt repeated the pattern the case rests on: orders grew but profit did not follow, and the humanoid ramp was pushed to the customer's new schedule.
The quarter in detail
Sales growth from the previous quarter, filed figures.
Earnings per share $0.14 against $0.15 expected.
The evidence under this - 5 claims
Management says currency cost $3.4M of operating income against a year earlier; without it adjusted operating margin would have been about 8.8% by its own reckoning, which no filing verifies.
The annual report says many backlog orders can be cancelled without penalty (C13), so record bookings do not guarantee revenue.
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
What management did with the money
Insiders in 2026Q2: 5 purchases and 0 sales, from their Form 4 filings.
The price, and where we disagree
In short. Fair. The price is about 87% of what we think the business is worth, at an 8% yearly return.
The shares tripled in a year to $151.78 on the robot story, then fell 27.2% on the day of the Q2 2026 results and 24% more to $54.24 by 3 November, and another 24% to $41.22 after the Q3 results.
Chip-equipment spending is at a record and orders topped $100M in Q3 2026. Short sellers held 13.8% of the shares available to trade at September's count, so the market is split.
The evidence under this - 4 claims
- 2026-11-04editedprice path extended to the 3 November close
- 2026-11-04editedeighth quarter at or above 1.0
How we value it
- Method
- Cash the business will produce, in three stages
- Required return
- 8%
- Long-run growth
- 4%
- Moat
- No moat
| Bear | Base | Bull | |
|---|---|---|---|
| Sales growth, years 1 to 3 | 4.5%, 3.5% | 9.1%, 7% | 11.4%, 8.8% |
| Normal operating margin | 12.5% | 15.7% | 17.2% |
| Return on new capital after year ten | 8% | 8% | 11% |
| Value a share | $37.85 | $50.97 | $70.32 |
- Price
- $44.21
- Priced on
- 6 Nov
- Price as a share of the base value
- 87%
- Starting growth the price pays for
- -0.1%
- Yearly return the price offers on the base case
- 9%
- Risk check: valued at 10%, the rate for a cyclical or indebted business
- $39.31
Where each figure comes from
| Figure | Source | Where exactly |
|---|---|---|
| Sales, the last twelve months | Filed report | Quarterly report (10-Q) for the period to 3 Oct 2026, filed 4 Nov 2026; the four quarters to that date. |
| Operating margin today | Filed report | Quarterly report (10-Q) for the period to 3 Oct 2026, filed 4 Nov 2026; the four quarters to that date. |
| Tax rate | Filed report | Quarterly report (10-Q) for the period to 3 Oct 2026, filed 4 Nov 2026; the four quarters to that date. |
| Sales per dollar of new capital | Filed report | Annual report (10-K) for the period to 31 Dec 2025, filed 27 Feb 2026: the year's sales over its operating capital. |
| Shares | Data vendor | FMP's count of listed shares, since the filed diluted count is on another basis (a split since, a second class or a depositary ratio). |
| Cash and investments | Filed report | Quarterly report (10-Q) for the period to 3 Oct 2026, filed 4 Nov 2026; the balance sheet on that date. |
| Debt | Filed report | Quarterly report (10-Q) for the period to 3 Oct 2026, filed 4 Nov 2026; the balance sheet on that date. |
| Sales growth, years 1 to 3 | Analysts' forecasts | FMP's consensus for the years to 31 Dec 2026, 31 Dec 2027 and 31 Dec 2028: the average of 2 analysts' revenue estimates, 10.2%, 7.6%. FMP publishes how many analysts, not who they are. |
| Normal operating margin | Analysts' forecasts | FMP's consensus operating margin for the year to 31 Dec 2028, as it stood when the value was struck on 10 Nov 2026, the average of 2 analysts' estimates, less stock pay: 15.7% in the base case. FMP publishes how many analysts, not who they are. |
| Return on new capital after year ten | Our method's rule | Set by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate. |
| The bear and bull cases | Our method's rule | Our method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin. |
| Price | Market price | FMP's closing price on 6 Nov 2026. |
What each case rests on
Bear caseGrowth runs at half the analysts' path, 4% and 4%, the margin settles a fifth lower at 12.5%, and new capital earns only the 8% rate: the downturn test.
Base caseRevenue grows 9% and 7% over three years, the analysts' path (C58), then fades toward 4%, closing 30% of the gap each year; the margin moves to 15.7%, the analysts' year-three figure after stock pay.
Bull caseGrowth runs a quarter above the analysts' path, 11% and 9%, the margin reaches 17.2%, and new capital earns 11%.
What moves the base value
| Lower | Higher | |
|---|---|---|
| Growth in years 1 to 3, a quarter lower or higher | $48.93 | $53.11 |
| The normal margin, 15% lower or higher | $43.28 | $58.65 |
| Capital per dollar of growth, a quarter more or less | $48.96 | $52.17 |
| Return on new capital after year ten, at the rate or one step up | $50.97 | $61.04 |
| The rate, a point higher or lower | $41.37 | $66.93 |
| Long-run growth a point lower | $49.82 | - |
Value a share as growth and margin change
| Normal margin ↓ · growth → | 50% | 75% | 100% | 125% | 150% |
|---|---|---|---|---|---|
| 12.6% | $38.03 | $39.34 | $40.72 | $42.17 | $43.70 |
| 14.1% | $42.52 | $44.14 | $45.84 | $47.64 | $49.54 |
| 15.7% | $47.01 | $48.93 | $50.97 | $53.11 | $55.37 |
| 17.3% | $51.50 | $53.73 | $56.09 | $58.58 | $61.20 |
| 18.8% | $55.98 | $58.53 | $61.22 | $64.05 | $67.04 |
Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.
How we read the multiple
Counting its cash, buyers pay about $484M for the whole business. That is about $17 for each $1 of operating profit VPG has averaged over eight years, the profit from the business itself, and about $8 for each $1 its 2028 plan would earn.
So the price is a normal one only if the plan works in full. The plan needs about 15 cents of operating profit on each dollar of sales; VPG's best year was 12.4 cents.
Against its own history. Buyers are paying far more than their usual price for each dollar of sales and profit, because they are pricing the plan rather than the record.
The evidence under this - 4 claims
- If Q2 2026's $3.3M currency hit reverses and the cost programme delivers its $20M, the target is closer than the 2.7% margin of 2025 suggests; management's own bridge put Q2 cash profit near $9M rather than $5.5M (C37).
- The humanoid option is sized in the target only at 50% a year; a real volume ramp at $150 to $250 a robot is not in the $60M.
- 2026-11-04editedre-struck at the 3 November close and the 3 October balance sheet
- 2026-11-06editedre-struck at the 2026-11-05 close of $41.22 after the shares fell 24% from the 2026-11-03 close
- VPG's operating margin has not exceeded 12.4% in any year since it listed in 2010 (C24); the target is above its best year.
- Q2 2026 adjusted operating margin was 1.7%, and cost savings delivered were $1.6M of the $6M planned for 2026 at mid-year.
- The model already carries about $5M a year of new head-office and IT cost.
- Only two analysts publish estimates, so this is two people's arithmetic rather than a market-wide view.
- Analysts may be allowing for the cost programme and a currency reversal that management has not put in the model separately.
Priced against its rivals
None of the listed rivals above sells the same thing to the same buyers as a large part of what it does. A price comparison needs at least two, so the price is judged against its own history instead.
Private or foreign rivals that cannot be priced: KOA Corporation, Bourns, Inc., TT Electronics plc, Susumu Co., Ltd., Isabellenhutte Heusler GmbH, Caddock Electronics, Inc., Flat Dashi, HBK (Spectris plc), Tokyo Sokki Kenkyujo Co., Ltd. (TML), Kyowa Electronic Instruments, Zemic, Utilcell, Air-Weigh, Vehicle Weighing Systems, ABB Ltd, IMS Messsysteme, Fuji Electric, Kistler Group.
The bet: what it pays if it works
This bet is on one business only: force sensors for humanoid robots. Everything else VPG makes is counted separately, at the price this thesis would call fair for it, and that covers a little over half of today's company value.
So today's price asks the humanoid line for far more than management's own target. If it hits that target the company is still worth less than today, which makes it an expensive bet. If it comes to nothing, the rest is still worth well below the price.
| Humanoid robot force sensing revenue in two to three years | Humanoid robots a year at volume content needed | At the stated multiple |
|---|---|---|
| $4.00M | about 20.0K at 100% kept | 0.8× |
| $13.50M (the big win) | about 67.5K at 100% kept | 0.8× |
| $26.00M | about 130.0K at 100% kept | 0.9× |
To pay 2× (a Fair bet) it would need about $300.22M of Humanoid robot force sensing revenue (about 1.5M humanoid robots a year at volume content); to pay 5× (a Cheap bet), about $1.02B of Humanoid robot force sensing revenue (about 5.1M humanoid robots a year at volume content), at the same multiple.
Each row is Humanoid robot force sensing alone, plus the rest of the company (Sensors, Weighing Solutions and Measurement Systems, without the humanoid line) counted at about $515.44M.
The steps it has to take
- Done First humanoid customer issues a vendor nomination letter
- Slipped Q2 2026 humanoid revenue more than doubles Q1's $0.6M, as management said it could due 2027-02
- Slipped Humanoid sales above $1M in a quarter due 2027-02-10
- Not started A humanoid purchase order disclosed with volume and price, or humanoid revenue above $2M in a quarter due 2027-06
- Not started Humanoid revenue above $10M in a year due 2028-03
The detail behind the label
The evidence under this - 5 claims
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
- VPG's operating margin has not exceeded 12.4% in any year since it listed in 2010 (C24); the target is above its best year.
- Q2 2026 adjusted operating margin was 1.7%, and cost savings delivered were $1.6M of the $6M planned for 2026 at mid-year.
- The model already carries about $5M a year of new head-office and IT cost.
- If Q2 2026's $3.3M currency hit reverses and the cost programme delivers its $20M, the target is closer than the 2.7% margin of 2025 suggests; management's own bridge put Q2 cash profit near $9M rather than $5.5M (C37).
- The humanoid option is sized in the target only at 50% a year; a real volume ramp at $150 to $250 a robot is not in the $60M.
- 2026-11-04editedre-struck at the 3 November close and the 3 October balance sheet
- 2026-11-06editedre-struck at the 2026-11-05 close of $41.22 after the shares fell 24% from the 2026-11-03 close
Where we disagree with the market
Record orders and a humanoid ramp mean the 2028 plan, a 15% operating margin, is on its way.
The orders are real, but the extra revenue is not becoming profit, and the price already pays for a margin never reached.
Analysts' 2028 forecasts are simply the company's plan, and every analyst rates the shares a buy. They read the orders. The accounts for each business show the extra revenue being spent on new staff, materials and head office before it becomes profit.
The evidence against us is management's own sum: without currency, an unusual mix of products and the delayed shipments, Q2 2026 would have earned about $9M before interest, tax and depreciation rather than $5.5M.
What analysts say, and the evidence
The evidence under this - 6 claims
- Only two analysts publish estimates, so this is two people's arithmetic rather than a market-wide view.
- Analysts may be allowing for the cost programme and a currency reversal that management has not put in the model separately.
- Management argues the spending is the price of capacity already ordered by customers and that profit follows once the new staff are productive; the Q1 2026 Sensors segment margin was 14.6%.
- Part of the unallocated rise is the 2026 move of share-based pay out of segment figures, which is presentation rather than new cost.
- 2026-11-04editedQ3 repeated the pattern for a second quarter
- The bridge was proposed by a sell-side analyst and accepted by the CFO, not reconciled in any filing.
- Even the $9M is a 10.7% cash profit margin, below the 11.1% of Q2 2025 and far below the 18.5% to 20.5% target.
What could go wrong, and how we would know
The risks
- We may be early. Currency cost $3.4M in Q3; if it fades and the cost programme lands, Q4 and 2027 could show the jump management expects.
- A real robot ramp. The first humanoid customer plans hundreds to thousands of robots a week, now on an updated schedule; if it happens, sales could beat any plan.
- The chip cycle turns. Test-equipment sales fell by a fifth in 2024; a downturn would drain the waiting orders the case rests on.
- Factories in Israel. Its main plants are there, so war or a stronger shekel hits output and costs directly.
- A family controls the vote. A trust run partly by the chief executive holds 27.4% of the votes, through ten-vote shares.
The evidence under this - 7 claims
- The bridge was proposed by a sell-side analyst and accepted by the CFO, not reconciled in any filing.
- Even the $9M is a 10.7% cash profit margin, below the 11.1% of Q2 2025 and far below the 18.5% to 20.5% target.
- VPG's costs sit largely in Israel and India while it sells in dollars (the 10-K's foreign currency section), so a weaker dollar is a standing exposure, not a one-off.
- The Q4 2025 call attributed that quarter's shortfall to $3M of different headwinds (C38): each weak quarter has carried its own explanation.
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
- 2026-11-04editedQ3 2026 orders added
Management says currency cost $3.4M of operating income against a year earlier; without it adjusted operating margin would have been about 8.8% by its own reckoning, which no filing verifies.
What we still do not know
- How much humanoid sales were in Q3 2026, and when the customer's updated schedule starts to ramp.
- How much of Sensors is resistors for chip testing and how profitable that part is. VPG reports the two businesses together.
- How big the market for ultra-precise resistors is. No outside body publishes it.
The evidence under this - 5 claims
- On the Q1 2026 call management said Q2 humanoid revenue could more than double the $0.6M of Q1; it roughly halved (C40).
- The nomination letter is not a purchase order and carries no disclosed volume or price; the ramp is the customer's forecast relayed by VPG.
- IFR counts about 7,000 humanoids sold worldwide in 2025, many for research rather than production (C33), so a thousands-a-week ramp would be a step change for the whole industry.
- 2026-11-04editedthe Q3 release moved the ramp to the customer's updated schedule and gave no figure
- IFR's count excludes household and military humanoids and may undercount Chinese makers, so the true 2025 unit base could be larger.
- Prototype robots carry more sensing content per unit than production ones, so the $400 to $500 figure may understate 2025 content.
- VPG's own risk factors say foil resistors and foil strain gages are also produced by competitors principally located in China, so the technology is not unique to VPG.
- Sensors gross margin was 31.5% in Q2 2026 and 28.5% in Q4 2025 - not what a part with no substitute usually earns, which says either the foil niche is a small part of the segment or its price is not set by scarcity.
- Thin film keeps closing the gap: a 5 ppm, 0.01% chip is already qualified for space by ESCC.
What would change our view
- Neutral→AttractiveThe price falls 20% under fair value
It needs:
- ○The share price falls to about $40.78, 80% of what we think the business is worth.about ≈$40.32 today, 26% below the last close
- Neutral→UnattractiveThe price runs 20% above fair value
It needs:
- ○The share price rises to about $61.16, 20% above what we think the business is worth.about ≈$63.46 today, 16% above the last close
- Reopens the researchThe humanoid ramp is contracted
It needs:
- ○VPG discloses a humanoid order with a volume and a price, or humanoid sales pass $2M in a quarter.watched as it happens
We would also be wrong if
- Sensors orders fall below what it ships for two quarters running, which would weaken the case further.
What is coming
- 3 November 2026 Q3 2026 results: Whether record backlog turns into profit: adjusted operating margin against 5%, Sensors profit against Sensors revenue, humanoid sales against Q2's $0.32M.
Every dated event ahead
- 3 November 2026 Q3 2026 results: Whether record backlog turns into profit: adjusted operating margin against 5%, Sensors profit against Sensors revenue, humanoid sales against Q2's $0.32M.
- February 2027 Q4 2026 results and the FY2026 10-K: Whether the $6M of 2026 cost savings arrived and selling and head-office cost per sales dollar finally fell, the first year of the target model.
- April 2027 2027 proxy statement: Whether a 2026 bonus was paid on adjusted EBITDA and margin, and how the pay goals were set against the 15% operating margin target.
Since we wrote this
- 9 NovPrice movePrice leg of route P1 met; margin leg and humanoid milestone notThe shares touched the route's price line on 5 November and then rose 7.3%. The margin is still 4.9% against 8%, and the humanoid sales step slipped to February.
- 9 NovThesis reviewNeutral: priced at 83% of a value near $53.57Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits inside the 20% margin of safety.
- 6 NovPrice moveShares fell 24%; the price half of our better-view route is metAt 16.7 times average operating profit the price is under the 18 line, but the margin is 4.9% against the 8% the route also needs, so the view holds.
- 4 NovEarningsQ3 orders hit a record but profit again lagged revenueAdjusted operating margin was 4.9%, below the 5% line, and Sensors profit fell 6.1% on 21.3% more revenue. The price fell 24% but still pays for the plan.
- 2 NovBet moveBet re-struck: Priced for success to Safe, little upsideRe-priced at the 30 October close.
- 28 OctBet moveBet re-struck: Safe, little upside to Priced for successRe-priced at the 27 October close.
- 23 OctBet moveBet re-struck: Priced for success to Safe, little upsideRe-priced at the 22 October close.
- 5 OctThesis reviewThe bet now names what it ridesThe owner asked that every bet name the macro trend behind it, after BWXT's bet was missing its chief executive's case for nuclear over gas.
- 4 OctThesis reviewOwner's checklist: revenue streams, cost of growth, management, catalystsThe owner's checklist found the method silent on who runs the company, what growth costs, where the money comes from and what is dated ahead; this pass fills those four blocks from the proxy and filings.
- 28 SepThesis writtenUnattractive, medium convictionWritten seven weeks after Q2 2026 results cut the shares by a quarter, with orders at records and profit near zero.
Also checked 6 times with nothing new to act on.
Sources 23
Sources - 23
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-02-27Item 1 business description, segments and brands, the design-win description, qualifications, competition section, backlog cancellation language, customer concentration (no customer above 10%), Israel manufacturing, export-control self-disclosure; income statements for 2023-2025; revenue by market sector; the segment note with unallocated G&A; the Kent facility gainbacksC01C02C06C07C08C13C15C19C20C24C31C41C42C49C50C53C54
- S02primarycompany filing2026-08-05Q2 2026 and six-month statements; segment note with segment operating income and unallocated G&A; backlog and book-to-bill by segment for five quarters; the 2024 Credit Agreement and revolver balancebacksC11C12C13C17C18C19C30C31C45C46C47C53
- S03primarycompany release2026-08-05headline figures, segment commentary, the FX and ERP explanations, Q3 2026 guidance of $84M to $89M, the non-GAAP redefinition to exclude share-based pay, the balance sheet and cash flow
During the quarter, we received a vendor nomination letter from our initial humanoid robotics customer, positioning us to support their planned production ramp of next-generation humanoid robots in the second half of 2026.
backsC17C21C30C31C36C39 - S04primarytranscript2026-08-05Q2 2026 earnings call transcriptdata/cache/transcripts/VPG-2026Q2.json (FMP earning-call-transcript, quarter label 2026Q2, call held 2026-08-05)humanoid bookings and sales; the vendor nomination letter; the second humanoid customer re-evaluating its designs; the $135.8M backlog; the management bridge to about $9M of adjusted EBITDA; price increases; three analysts' questions (Lake Street, B. Riley, Sidoti)
Humanoid-related bookings were approximately $500,000 and sales were $320,000 in the second quarter.
backsC12C14C21C36C37C40C46C48 - S05primarytranscript2026-05-12Q1 2026 earnings call transcriptdata/cache/transcripts/VPG-2026Q1.json (FMP earning-call-transcript, quarter label 2026Q1, call held 2026-05-12)the three-year target operating model (8% to 10% organic growth, 46.5% gross margin, 14.5% to 15.5% operating margin); the humanoid assumption of 50% a year from a $4M 2025 base; the promise that Q2 humanoid revenue would more than double; content per robot at low and high volume
the content of all the sensing parts within the robot would be between 400 to 500, while if the volume moves to many hundreds or more than that, we believe -- again, there is no solid or final negotiation with anybody, but we believe that the expectation is to go to the round about, I would say, 150 to 250 levels.
backsC21C22C23C39C40 - S06primarytranscript2026-02-11Q4 2025 earnings call transcriptdata/cache/transcripts/VPG-2025Q4.json (FMP earning-call-transcript, quarter label 2025Q4, call held 2026-02-11)the Q4 2025 headwinds; humanoid orders of $0.8M in Q4 and about $1M in January; the new CBPO and COO organisation and its cost
Our fourth quarter adjusted gross margin of 37% was impacted by $3 million of headwinds, including unusual unfavorable product mix, inventory reductions, and discrete inventory and manufacturing impact.
backsC38 - S07primarycompany release2026-02-11Q4 2025 results, the 2026 goals (mid- to high-single-digit growth, $6M of cost reductions) and the Q1 2026 revenue guide
we expect net revenues to be in the range of $74 million to $80 million
backsC39 - S08primarycompany filing2026-04-09the two share classes, ten votes per Class B share, and the family trust co-trusteed by the chief executive holding 27.4% of the votebacksC32C51C52C54
- S09primarycompany filing2026-02-13a named rival's own description of its thin film SMD resistor leadership and its $759.3M Resistors segment; the licence under which VPG uses the Vishay name; its account of Bulk Metal foil as the most precise resistor technologybacksC02C43
- S10primarycompany filing2026-02-23a force torque sensor maker listing humanoids among its applications, and the $223.9M it paid for ATI Industrial Automation in 2021backsC09
- S11primaryother2026-09-28Vishay Sfernice PHR product page - ESCC-qualified thin film precision chip resistors Vishay Intertechnologythe tightest drift a rival thin film part qualified for space use specifies, which bounds the gap foil is sold on
ESCC 4001/023 Qualified High Precision (5 ppm, 0.01 %), Thin Film Chip Resistors FEATURES Load life stability at ± 70 °C for 2000 h: 0.15 % under Pn Low temperature coefficient down to ± 5 ppm/°C
backsC04 - S12primarycompany release2022-07-25the qualified (QPL) military established-reliability foil resistor and its drift and tolerance specification
The RNC90Z TCR limit of ±2 ppm/°C over the extended range of -55°C to +175°C is a significant improvement over the existing RNC90Y specification.
backsC03 - S13primaryindustry data2026-09-03the rate of the chip-equipment build that drives the Sensors order book, measured by the industry association from members' billings
global semiconductor equipment billings increased 23% year-over-year to US$40.53 billion in the second quarter of 2026. Second quarter 2026 billings registered an 11% quarter-over-quarter growth.
backsC16 - S14primaryindustry data2026-09-24the installed base and annual flow of conventional industrial robots, the market humanoids are trying to enter
The global operational stock of industrial robots surged 9% to a record 5 million units in 2025. This was driven by an 11% jump in annual installations: Factories worldwide installed more than 600,000 new units over the year. Installations are forecast to rise by 9% to 655,000 units in 2026 and reach 806,000 units in 2029.
backsC34 - S15secondarynews2026-09-21the only outside count of humanoid robots sold; also that many were bought for data collection and that household and military units are excluded
The International Federation of Robotics (IFR) estimated global sales of humanoid robots for industrial and professional service applications at around 7,000 units in 2025, Reuters reported after reviewing IFR data ahead of its official release.
backsC33 - S16secondaryvendor data2026-09-28Research pack, frozen at content/VPG/research-pack.jsoncontent/VPG/research-pack.jsonprice, 52-week range and returns, the analyst split and estimates, FINRA short interest, the insider window, the valuation ratiosbacksC25C26C27C28C29
- S17primarycompany filing2026-09-28the filer's own tagged annual operating income and revenue for every year since the 2010 spin-off, from which the operating margin history is struckbacksC24
- S18primarycompany filing2026-10-04selling, general and administrative cost, R&D, unallocated corporate cost, stock pay, capital spending and diluted shares per year; acquisition, buyback and revolver cash flows 2021-2025backsC50C53
- S19primarycompany filing2026-11-04Q3 2026 revenue, margins, segment bookings and revenue, the revised non-GAAP definition, adjusted free cash flow and the Q4 guidebacksC12C13C21C30C39C47C55C56C57
- S20primarycompany filing2026-11-04segment operating income, unallocated costs, operating income, cash and debt at 3 October, shares outstandingbacksC25C30C47C55C57
- S21tertiaryvendor data2026-11-04FMP daily closes for VPG to 3 November 2026the 3 November 2026 close of $54.24backsC25C27
- S22primarycompany filing2026-11-09trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share countbacksC59
- S23secondaryvendor data2026-11-09the analysts' average revenue and operating profit for the next three fiscal years, and the closebacksC58C59